Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.

Trial Profile

Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center record.
    • 23 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2015 to 1 Apr 2016.
    • 22 May 2013 Planned end date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top